We’re pleased to share that Dr. Gregory Penner, Chief Scientific Officer at NeoVentures Biotechnology Europe, will be participating in BIO-Europe Fall 2025. The event will be taking place November 3-5 in Vienna, Austria.

BIO-Europe Fall is Europe’s leading partnering conference for the global biotech and pharmaceutical industries. The event brings together innovators, investors, and strategic partners to advance scientific and commercial collaborations.

At this year’s event, Dr. Penner will meet with potential partners to discuss NeoVentures’ Aptamarker platform. The Aptamarker platform is our proprietary system for biomarker discovery that leverages aptamer technology to identify and validate molecular signatures of disease with precision and reproducibility.

Biomarker discovery has driven major advances in healthcare, but most traditional approaches rely on animal-produced antibodies. Researchers generate these antibodies by introducing human recombinant proteins into animals and harvesting the resulting antibodies. Maintaining commercial supply often requires continuous animal use.

Our Aptamarker platform eliminates the need for animals in biomarker discovery. It uses chemically synthesized DNA oligonucleotides applied directly to human biological samples.

Unlike traditional methods that train probes against single recombinant proteins, Aptamarker applies a deep library of 268 million probes to each sample. This allows direct interaction with proteins in their natural context, revealing structural and functional states as they exist in vivo. This is crucial because many diseases arise not from isolated proteins but from changes in protein function and interactions within biological systems.

Aptamarker is the only platform capable of characterizing these functional protein changes in any protein, from any species, offering a true paradigm shift in biomarker discovery.

NeoVentures Biotechnology Europe has joined NVIDIA Inception, a program designed to help startups evolve faster through cutting-edge technology and access to the latest technical resources from NVIDIA.

At NVB Europe, we’ve developed the Aptamarker Platform, a powerful, next-generation approach to High-Plex proteomics. Unlike traditional methods, this platform applies 268 million probes to every sample. As a result, we can comprehensively profile the entire protein landscape. This unmatched depth enables the identification of biomarkers related to disease stage, relapse versus remission, treatment response, and the risk of adverse side effects.

To fully unlock the value of this deep dataset, we’ve strategically integrated artificial intelligence at the core of our analysis. Consequently, we are able to transform complex molecular signals into clear, actionable insights. These insights are essential for driving the advancement of precision and personalized medicine.

Furthermore, with the support of NVIDIA’s cutting-edge computational tools, we are significantly expanding our ability to model probe–protein interactions at the tertiary structural level. Thanks to this advancement, we can move beyond detecting whole proteins and begin identifying epitopes, specific regions within proteins, as highly predictive markers of disease progression or therapeutic response.

Moreover, as a proud member of the NVIDIA Inception program, and through our ongoing use of NVIDIA Cloud, we are well-positioned to accelerate therapeutic discovery. In turn, this collaboration is helping us deepen our understanding of disease mechanisms and establish a robust foundation for a new era of proactive, personalized healthcare.